Clearsign Technologies Corp. 8-K Summary
Business Context and Reporting Period
Clearsign Technologies Corp. (CLIR) filed a Current Report on Form 8-K on May 28, 2026, regarding a material definitive agreement. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Details
- Transaction Type: Firm-commitment underwritten public offering of common stock.
- Shares Issued: 777,780 shares (Firm Shares) at a public offering price of $4.33 per share.
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 116,667 additional shares.
- Net Proceeds: Approximately $2.94 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Working capital, research and development, marketing and sales, and general corporate purposes.
- Closing Date: Expected on or about June 1, 2026.
Material Changes and Agreements
The filing details the entry into an Underwriting Agreement with Newbridge Securities Corporation. Key contractual terms include:
- Lock-Up Period: The Company and its executive officers and directors agreed to a 90-day lock-up period from the date of the final prospectus supplement, restricting the sale or transfer of common stock or convertible securities.
- ATM Exception: The Company may sell shares pursuant to an existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC after 30 days from the Underwriting Agreement date.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or specific risk factors beyond standard underwriting contingencies. The closing of the offering is subject to customary conditions contained in the Underwriting Agreement. Legal validity of the securities was confirmed by counsel Mitchell Silberberg & Knupp LLP.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received upon settlement.
- Confirm whether the underwriter exercises the over-allotment option for the additional 116,667 shares.
- Review the final prospectus supplement for specific underwriting discounts and commission rates.
- Monitor the company's capital allocation to ensure proceeds are utilized for the stated purposes (R&D, working capital, etc.).